Perspectives on treatment needs in schizophrenia

British Journal of Psychiatry

Volumn 168, Issue MAY SUPPL. 29, 1996, Pages 9-16

  Meise, Ullrich ^a   Fleischhacker, W Wolfgang ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; MENTAL HEALTH CARE; PSYCHOPHARMACOTHERAPY; REHABILITATION; REVIEW; SCHIZOPHRENIA;

EID: 8944231645     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298267     Document Type: Review

References (106)

1. ANDREWS, G. (1991) The cost of schizophrenia revisited. Schizophrenia Bulletin, 17, 389-394.
2. ANTHONY, W. A. (1979) Principles of Psychiatric Rehabilitation. Baltimore: University Park Press.
3. ASARNOW, R. F., GRANHOLM, E. & SHERMAN, T. (1991) Span of apprehension in schizophrenia. In Handbook of Schizophrenia, Vol. 5: Neuropsychology, Psychophysiology and Information Processing (eds S. R. Steinhause, J. H. Gruzelier & J. Zubin). Amsterdam: Elsevier.
4. ATTKISSON, C., COOK, J., KARNO, M., et al (1992) Clinical services research. Schizophrenia Bulletin, 18, 561-626.
5. BACHRACH, L. L. (1981) Continuity of care for chronic mental patients: a conceptual analysis. American Journal of Psychiatry, 138, 1449-1456.
6. _ (1983) Deinstitutionalization: an overview of the issues. Bulletin of the Menninger Clinic, 47, 63-188.
7. _ (1992) Psychosocial rehabilitation and psychiatry in the care of long-term patients. American Journal of Psychiatry, 149, 1455-1463.
8. BARNAS, C., STUPPACK, C., MILLER, C., et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial vs. haloperidol. International Clinical Psychopharmacology, 7, 23-27.
9. BELLACK, A. S. & MUESER, K. T. (1993) Psychosocial treatment for schizophrenia. Schizophrenia Bulletin, 19, 317-336.
10. BLACKWELL, B. (1973) Drug therapy: patient compliance. New England Journal of Medicine, 289, 249-252.
11. BLEULER, E. (1908) Die Prognose der Dementia Praecox - Schizophreniegruppe. Allgemeine Zeitschrift für Psychiatrie, 65, 436-464.
12. BRENNER, H. D., HODEL, B., RODER, V., et al (1992) Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia. Schizophrenia Bulletin, 18, 21-26.
13. CARPENTER, W. T., HEINRICH, D. W. & ALPHS, L. D. (1985) Treatment of negative symptoms. Schizophrenia Bulletin, II, 440-452.
14. _ HANLON, T. E., HEINRICHS, D. W., et al (1990) Continuous versus targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry, 147, 1138-1148.
15. CHEN, M. K. (1978) A quantitative index of access to primary medical care for health planning. Socioeconomic Science, 12, 295-301.
16. CHEUNG, H. K. (1981) Schizophrenics fully remitted in neuroleptics for 3-5 years: to stop or continue drugs? British Journal of Psychiatry, 138, 490-494.
17. CLOZAPINE STUDY GROUP (1993) The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. British Journal of Psychiatry, 163, 150-154.
18. DAVIS, J. M. (1985) Antipsychotic drugs. In Comprehensive Textbook of Psychiatry IV, Vol. 2 (4th edn) (eds H. I. Kaplan & B. J. Sadock), pp. 1481-1513. Baltimore: Williams & Wilkins.
19. _ & CASPER, R. (1977) Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs, 14, 260-282.
20. _ & ANDRIUKAITIS, S. (1986) The natural course of schizophrenia and effective maintenance drug treatment. Journal of Clinical Psychopharmacology, 6 (suppl. 1), 2S-10S.
21. DEUTSCHER BUNDESTAG (1975) Bericht über die Lage der Psychiatrie in der Bundesrepublik Deutschland, Drucksache 7/4200, pp. 79-82. Bonn: Hans Heger.
22. DOHRENWEND, B. P. (1980) Mental Illness in the United States. New York: Praeger.
23. DRAKE, R. E., WALLACH, M. A. & HOFFMAN, J. S. (1989) Housing instability and homelessness among aftercare patients of an urban state hospital. Hospital and Community Psychiatry, 40, 46-51.
24. DWORIN, J., GREEN, J. A. & YOUNG, H. H. (1964) A follow-up study of relationships between distance from the clinic, degree of disability and requests for psychiatric treatment. Journal of Clinical Psychology, 20, 393-395.
25. FALLOON, I. R. D., BOYD, J. L., MCGILL, C. W., et al (1982) Family management in the prevention of exacerbations of schizophrenia: a controlled study. New England Journal of Medicine, 24, 1437-1440.
26. FENTON, W. S. & MCGLASHAN, T. H. (1987) Sustained remission in drug-free schizophrenic patients. American Journal of Psychiatry, 144, 1306-1309.
27. FLEISCHHACKER, W. W. (1995) New drugs for the treatment of schizophrenic patients. Acta Psychiatrica Scandinavica, 91 (suppl. 388), 24-30.
28. _ & WHITWORTH, A. B. (1994) Adverse effects of antipsychotic drugs. Current Opinion in Psychiatry, 7, 71-75.
29. _, MEISE, U., GUENTHER, V., et al (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scandinavica, 89 (suppl. 382), 11-15.
30. FLEKKOY, K. (1987) Epidemiologie und Genetik. In Psychiatrie der Gegenwart 4: Schizophrenien (eds K. P. Kisker, H. Lauter, J. E. Meyer, et al), pp. 119-153. New York: Springer.
31. GAEBEL, W. & PIETZCKER, A. (1987) Prospective study of course of illness in schizophrenia: Part III. Treatment and outcome Schizophrenia Bulletin, 13, 307-316.
32. GLAZER, W. M. & KANE, J. M. (1992) Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry, 53, 426-433.
33. GMÜR, M. (1986) Schizophrenieverlauf und Entinstitutionalisierung. Stuttgart: Enke.
34. _ & TSCHOPP, A. (1988) Die Behandlungskontinuität bei Schizophrenen Patienten in der Ambulanz. Nervenarzt, 59, 727-730.
35. GOERING, P., WASYLENKI, D., FARKAS, M., et al (1988) What difference does case management make? Hospital and Community Psychiatry, 39, 272-276.
36. GOFFMAN, E. (1961) Asylums: Essays on the Social Situation of Mental Patients and Other Inmates. New York: Doubleday-Anchor.
37. GOLDSTROM, I. D. & MANDERSCHEID, R. W. (1982) The chronically mentally ill: a descriptive analysis from the Uniform Client Data Instrument. Community Support Service Journal, 2, 4-9.
38. GUENTHER, V. & MEISE, U. (1990) Compliance - Ein komplexes Problem. Wiener Medizinische Wochenschrift, 140, 365-369.
39. GUNDERSON, J. G. & MOSHER, L. R. (1975) The cost of schizophrenia. American Journal of Psychiatry, 132, 901-906.
40. HALL, W., GOLDSTEIN, G., ANDREWS, G., et al (1985) Estimating the economic costs of schizophrenia. Schizophrenia Bulletin, 11, 598-610.
41. HARDING, C. M., BROOKS, G. W., ASHIKAGA, T., et al (1987) The Vermont longitudinal study of persons with severe mental illness. II. Long-term outcome of subjects who met retrospectively DSM-III criteria for schizophrenia. American Journal of Psychiatry, 144, 718-735.
42. _, ZUBIN, J. & STRAUSS, J. (1988) Chronicity in schizophrenia: fact, practical fact, or artifact? Hospital and Community Psychiatry, 38, 477-486.
43. HATFIELD, A. B. (1989) Serving the unserved in community rehabilitation programs. Psychosocial Rehabilitation Journal, 13, 71-82.
44. HERZ, M. I., GLAZER, W. M., MOSTERT, M. A., et al (1991) Intermittent vs maintenance medication in schizophrenia: two-year results. Archives of General Psychiatry, 48, 333-339.
45. HIRSCH, S. R. (1988) Psychiatric Beds and Resources: Factors Influencing Bed Use and Service Planning. London: Gaskell.
46. HOGARTY, G. E., ANDERSON, C. M., RESII, D. J., et al (1991) Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled trial on relapse and adjustment. Archives of General Psychiatry, 48, 340-347.
47. HOULT, J, REYNOLDS, I. & CHARBONNEAU-POWIS, M. (1983) Psychiatric hospital versus community treatment. Australian and New Zealand Journal of Psychiatry, 17, 160-167.
48. JARMAN, B., HIRSCH, S., WHITE, P., et al (1992) Predicting psychiatric admission rates. British Medical Journal, 304, 1146-1151.
49. JOHNSON, D. A. W., LUDLOW, J. M., STREET, K., et al (1983) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry, 151, 634-638.
50. JOLLEY, A. G., HIRSCH, S. R., MORRISON, E., et al (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. British Medical Journal, 298, 985-990.
51. KANE, J. M. (1987) Treatment of schizophrenia. Schizophrenia Bulletin, 13, 133-156.
52. _, HONIGFELD, G., SINGER, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
53. _ & MARDER, S. R. (1993) Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin, 19, 287-302.
54. KIRCH, D. G., KEITH, S. J. & MATTHEWS, S. M. (1992) Research on first-episode psychosis: report on a National Institute of Mental Health Workshop. Schizophrenia Bulletin, 18, 179-182.
55. KISSLING, W. (1991) The current unsatisfactory state of relapse prevention in schizophrenic psychoses: suggestions for improvement. Clinical Neuropharmacology, 14 (suppl 2), S33-S44.
56. KOEGEL, P., BURNAM, M. A. & FARR, R. K. (1988) The prevalence of specific psychiatric disorders among homeless individuals in the inner city of Los Angeles. Archives of General Psychiatry, 45, 1085-1092.
57. _, KANE, J. M., BARNES, T. R. E., et al (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In Guidelines for Relapse Prevention in Schizophrenia (ed. W. Kissling), pp. 155-163. Berlin: Springer.
58. KORAN, L. M., SOX, H. C., JR, MARTON, K. I., et al (1989) Medical evaluation of psychiatric patients. I. Results in a state mental health system. Archives of General Psychiatry, 46, 733-740.
59. KRAEPELIN, E. (1896) Psychiatrie (5th edn). Leipzig: Barth.
60. KURZ, M., HUMMER, M., OBERBAUER, H., et al (1995) Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology, 118, 52-56.
61. LAM, D. H. (1991) Psychosocial family intervention in schizophrenia: a review of empirical studies. Psychological Medicine, 21, 423-441.
62. LEFF, J., KUIPERS, L., BERKOWITZ, R., et al (1985) A controlled trial of social intervention in the families of schizophrenic patients: two-year follow-up. British Journal of Psychiatry, 146, 594-600.
63. LIBERMAN, R. P. (1982) Assessment of social skills. Schizophrenia Bulletin, 8, 63-83.
64. _, MUESER, K. T. & WALLACE, C. J. (1986) Social skills training for schizophrenic individuals at risk for relapse. American Journal of Psychiatry, 143, 523-526.
65. LIEBERMAN, J. A. (1993) Understanding the mechanism of action of atypical antipsychotic drugs: a review of compounds in use and development. British Journal of Psychiatry, 163 (suppl. 22), 7-18.
66. _, ALVIR, J. M., WOERNER, M., et al (1992) Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophrenia Bulletin, 18, 351-371.
67. MALHOTRA, A. K., LITMAN, R. E. & RICKAR, D. (1993) Adverse effects of antipsychotic drugs. Drug Safety, 9, 429-436.
68. MARDER, S. R. (1992) Risperidone: clinical development: North American results. Clinical Neuropharmacology, 15 (suppl. 1, Pt A), 92A.
69. _ & MEIBACH, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
70. _, WIRSCHING, W. C., VAN PUTTEN, T., et al (1994) Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Archives of General Psychiatry, 51, 280-287.
71. MCGLASHAN, T. H. (1988) A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophrenia Bulletin, 14, 515-542.
72. MEISE, U., ROESSLER, W., SCHETT, P., et al (1992) Zur Behandlungssituation psychish Kranker: Auswertungsergebnisse administrativer daten schizophrener Patienten. In Rückfallsprophylaxe Schizophrener Patienten (ed. P. Koenig), pp. 67-87. Vienna: Springer.
73. _, KURZ, M. & FLEISCHHACKER, W. W. (1994) The antipsychotic maintenance treatment of schizophrenic patients: is there a consensus? Schizophrenia Bulletin, 20, 215-225.
74. _, KEMMLER, E., KURZ, M. & ROESSLER, W. (1996) Die standort qualität alsgrundlage psychiatrischer versorguags planung. Gesundheitswesen, 58, 64-73.
75. MORRISON, R. L. & BELLACK, A. S. (1987) Social functioning of schizophrenic patients: clinical and research issues. Schizophrenia Bulletin, 13, 715-725.
76. MULKERN, V. M. & MANDERSCHEID, R. W. (1989) Characteristics of community support program clients in 1980 and 1984. Hospital and Community Psychiatry, 40, 165-172.
77. NUECHTERLEIN, K. H. & DAWSON, M. E. (1984) Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophrenia Bulletin, 10, 160-203.
78. PIETZCKER, A. & GAEBEL, W. (1987) Prospective study of course of illness in schizophrenia: Part I. Outcome at 1 year. Schizophrenia Bulletin, 13, 287-297.
79. _, _, KOPCKE, W., et al (1993) Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: two-year results of a German multicenter study. Journal of Psychiatric Research, 27, 321-339.
80. POLLACK, E. S. (1977) Mental Health Demographic Profile for Health Service Planning. National Centre for Health Statistics, Statistical Notes for Health Planners No. 4, DHEW (HRA) 77-1237. Rockville: Fishers Lane.
81. REGIER, D. A., MYERS, J. K., KRAMER, M., et al (1984) The NIMH Epidemiologic Catchment Area Program. Archives of General Psychiatry, 41, 934-941.
82. RICE, D. P., KELMAN, S. & MILLER, L. S. (1992) The economic burden of mental illness. Hospital and Community Psychiatry, 43, 1227-1232.
83. ROBINS, L. N., HELZER, J. E., WEISSMAN, M. M., et al (1984) Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry, 41, 949-958.
84. ROESSLER, W., RIECHER, A., LOEFFLER, E., et al (1991) Community care in child psychiatry. Social Psychiatry and Psychiatric Epidemiology, 26, 28-33.
85. _, FAETKENHEUER, B. & LOEFFLER, W. (1993) Soziale Rehabilitation Schizophrener. Stuttgart: Enke.
86. ROSEN, B. M., GOLDSMITH, H. F. & REDICK, R. W. (1979) Demographic and social indicators: uses in mental health planning in small areas. World Health Statistics, 32, 11-101.
87. SARTORIUS, N., JABLENSKY, A., ERNBERG, G., et al (1987) Course of schizophrenia in different countries: some results of a WHO comparative 5-year follow-up study. In Search for the Causes of Schizophrenia (eds H. Haefner, W. F. Gattaz & W. Janzarik), pp. 107-113. New York: Springer.
88. SCHOOLER, N. R. (1985) Treatment of schizophrenia: maintenance strategies and pharmacologic tactics. In Controversies in Schizophrenia (ed. M. Alpert). New York: Guilford Press.
89. _ (1991) Maintenance medication for schizophrenia: strategies for dose reduction. Schizophrenia Bulletin, 17, 311-324.
90. SCHUBART, C., SCHWARZ, R., KRIMM, B., et al (1986) Schizophrenie und Soziale Anpassung. Berlin: Springer.
91. SHANNON, G. W., BASHSHUR, R. I. & LOVETT, J. E. (1986) Distance and the use of mental health services. Millbank Quarterly, 64, 302-330.
92. SHEPHERD, M., WATT, D., FALLOON, I., et al (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine, (monograph suppl. 15), 1-46.
93. STEIN, L. I. & TEST, M. A. (1980) Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation. Archives of General Psychiatry, 37, 392-397.
94. STOUDEMIRE, A. & THOMPSON, T. (1983) Medication noncompliance: systematic approaches to evaluation and intervention. General Hospital Psychiatry, 5, 233-239.
95. SYTEMA, S. (1991) Social indicators and psychiatric admission rates. A case-register study in The Netherlands. Psychological Medicine, 21, 177-184.
96. TALBOTT, J. A., GOLDMAN, H. H. & ROSS, L. (1987) Schizophrenia: an economic perspective. Psychiatric Annals, 17, 577-579.
97. THORNICROFT, G. (1991) Social deprivation and rates of treated mental disorder: developing statistical models to predict psychiatric service utilisation. British Journal of Psychiatry, 158, 475-484.
98. US PUBLIC HEALTH SERVICE (1961) Areawide Planning for Hospitals and Related Health Facilities, USPHS publication no. 855. Washington DC: US Government Printing Office.
99. WALLACE, C. J. (1993) Psychiatric rehabilitation. Psychopharmacology Bulletin, 29, 537-548.
100. WELLER, M. P. (1989) Mental illness - who cares? Nature, 339, 249-252.
101. WING, J. K. (1987) Rehabilitation, Soziotherapie und Prävention. In Psychiatrie der Gegenwart 4: Schizophrenien (eds H. P. Kiske, H. Lauter, J. E. Meyer, et al), pp. 352-355. Berlin: Springer.
102. WINOKUR, G. & TSUANG, M. (1975) Suicide in mania, depression and schizophrenia. American Journal of Psychiatry, 132, 650-651.
103. WIRSCHING, W. C. & MARDER, S. R. (1993) Drug treatment in schizophrenia. Current Opinion in Psychiatry, 6, 85-89.
104. WISTEDT, B., JORGENSEN, A. & WILES, D. (1982) A depot neuroleptic withdrawal study: plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology, 78, 301-304.
105. WORLD HEALTH ORGANIZATION (1980) International Classification of Impairments, Disabilities and Handicaps. Geneva: WHO.
106. WYATT, R. W. (1991) Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17, 325-351.